Healius Limited

ASX-HLS
Australian Securities Exchange
Healthcare Diagnostics & Research
Global Rank
#16678
Country Rank
#302
Market Cap
347.2 M
Price
0.478
Change (%)
2.10%
Volume
2.9 M

Healius Limited's latest marketcap:

347.2 M

As of 07/05/2025, Healius Limited's market capitalization has reached $347.2 M. According to our data, Healius Limited is the 16678th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 347.2 M
Revenue (ttm) 1.17 B
Net Income (ttm) -14,934,000
Shares Out 726.13 M
EPS (ttm) -0.02
Forward PE 0.00
Ex-Dividend Date 05/09/2025
Earnings Date 08/21/2025
Market Cap Chart
Data Updated: 07/05/2025

Healius Limited's yearly market capitalization.

Healius Limited has seen its market value drop from A$2.38 B to A$347.2 M since 2014, representing a total decrease of 85.42% and an annual compound decline rate (CAGR) of 16.74%.
Date Market Cap Change (%) Global Rank
07/05/2025 A$347.2 M -47.81% 16678
12/31/2024 A$994.8 M -16.2% 11622
12/29/2023 A$1.19 B -32.22% 9908
12/30/2022 A$1.75 B -43.13% 7427
12/31/2021 A$3.08 B 32.57% 5717
12/31/2020 A$2.32 B 35.15% 5713
12/31/2019 A$1.72 B 23.85% 6126
12/31/2018 A$1.39 B -26.49% 6215
12/29/2017 A$1.89 B -11.26% 5599
12/30/2016 A$2.13 B 74.36% 4790

Company Profile

About Healius Limited

Healius Limited is a leading provider of specialty diagnostic services in Australia, catering to both consumers and healthcare practitioners. The company delivers a comprehensive range of diagnostic solutions through its well-established network of facilities.

Business Segments

  • Pathology: Offers private medical laboratory and pathology services.
  • Imaging: Provides diagnostic imaging services.
  • Others: Includes additional healthcare-related services.

Brand Portfolio

Healius operates under several trusted brands, including:

  • Laverty Pathology
  • Dorevitch Pathology
  • QML Pathology
  • Western Diagnostic Pathology
  • Genomic Diagnostic
  • Vetnostics
  • TML Pathology
  • Abbott Pathology
  • IQ Pathology
  • Kossard
  • Gastrolab
  • Agilex Biolabs

Operations

The company manages an extensive network of:

  • Medical laboratories
  • Medical centers
  • Patient collection centers
  • Community imaging centers

Corporate Background

Originally incorporated in 1994 as Primary Health Care Limited, the company rebranded to Healius Limited in December 2018. Headquartered in Sydney, Australia, Healius continues to expand its diagnostic and healthcare services nationwide.

Frequently Asked Questions

  • What is Healius Limited's (ASX-HLS) current market cap?
    As of 07/05/2025, Healius Limited (including the parent company, if applicable) has an estimated market capitalization of $347.2 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Healius Limited global market capitalization ranking is approximately 16678 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.